• Cadrenal Therapeutics reported a Q1 net loss of USD 2.5 million, narrowing from USD 3.8 million a year earlier, while loss per share improved to USD 1.04 from USD 2.09.
• Total operating expenses fell to USD 2.5 million from USD 3.9 million, with R&D spend dropping to 771,508 from USD 1.67 million.
• Cash and cash equivalents totaled USD 2.3 million at March 31, 2026; it completed a USD 2.5 million financing on April 1.
• FDA End-of-Phase 2 meeting minutes guided a planned randomized, blinded, placebo-controlled Phase 3 trial of CAD-1005 in about 120 HIT patients, with a primary endpoint of new or worsening thrombotic events and a projected NDA submission in 2029.
• CEO Quang X. Pham said FDA guidance “clearly defined” the registration path, backing plans to move directly into Phase 3.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cadrenal Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605070830PRIMZONEFULLFEED9714966) on May 07, 2026, and is solely responsible for the information contained therein.